Use of Intravenous Ciprofloxacin in a Canadian Medical Centre

Karlowsky, J.A.; Gin, A.S.; Cooper, R.; Hoban, D.J.; Zhanel, G.G.
December 1999
Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p271
Academic Journal
Attempts to determine the frequency of IV ciprofloxacin use in treating Pseudomonas aeruginosa infections compared with other bacterial infections. Data collection; Results; Discussion.


Related Articles

  • Incidence and Microbial Profile of Chronic Suppurative Otitis Media at Gulbarga, Karnataka. C.S, VinodKumar; B.Y, Yuvaraj; Bushara; Rathod, Vandana; Sulatana, Shameem; D.S, Praveen; Kalsurmath, Suneeta // Indian Journal of Public Health Research & Development;Oct-Dec2012, Vol. 3 Issue 4, p231 

    Objective Chronic suppurative otitis media (CSOM) is a prevailing and notorious infection in developing countries causing serious local damage and threatening complications. Early and effective treatment based on the knowledge of causing micro organisms and their sensitivity results in good...

  • INFECTIONS & INFESTATIONS.  // Monthly Prescribing Reference;Sep2011, Vol. 27 Issue 9, p192 

    The article presents several drug prescriptions for the treatment of various infections and infestations. It says that amoxicillin capsules such as broad-spectrum penicillin are used to treat susceptible infections including ear/nose/throat (ENT). It tells that Augmentin XR from GlaxoSmithKline...

  • In-Vitro Efficacy of Synergistic Antibiotic Combinations in Multidrug Resistant Pseudomonas Aeruginosa Strains. Dundar, Devrim; Otkun, Metin // Yonsei Medical Journal;1/1/2010, Vol. 51 Issue 1, p111 

    Purpose: Combination antibiotic treatment is prefened in nosocomial infections caused by Pseudomonas aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in clinic. The aim of this study was to investigate the synergistic efficacy of...

  • Bacterial infections wiped out in a flash. Spinney, Laura // New Scientist;7/23/94, Vol. 143 Issue 1935, p18 

    Reports that destroying bacteria using special light-activated molecules could reduce the need to treat the whole body with antibiotics to fight the infections suffered by patients. Habitat of the bacterium Pseudomonas aeruginosa; Number of cases of septicemia caused by the bacterium; Side...

  • In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa. Yasmin, Firdous; Akhtar, Naeem; Hameed, Abdul // Pakistan Journal of Pharmaceutical Sciences;Sep2013, Vol. 26 Issue 5, p1041 

    Pseudomonas aeruginosa is an increasingly prevalent nosocomial human pathogen. Infections with multidrug- resistant (MDR) P. aeruginosa are currently a treatment challenge and requires search for better treatment options. Purpose of study: To determine in vitro synergistic effect of...

  • Volunteer and Clinical Studies with Carfecillin: A New Orally Administered Ester of Carbenicillin. Wilkinson, P. J.; Reeves, D. S.; Wise, R.; Allen, J. T. // British Medical Journal;5/3/1975, Vol. 2 Issue 5965, p250 

    Examines the efficiency of carfecillin for the treatment of Pseudomonas aeruginosa urinary infections. Measurement on the blood and urine levels of carbenicillin in 10 healthy volunteers and four patients with renal failure; Treatment of 35 inpatients with seven-day course of carfecillin;...

  • Pseudomonas aeruginosa isolates and their antimicrobial susceptibility pattern among catheterized patients at Jimma University Teaching Hospital, Jimma, Ethiopia. Bekele, Temesgen; Tesfaye, Amene; Sewunet, Tsegaye; Deti Waktola, Habtewold // BMC Research Notes;9/29/2015, Vol. 8 Issue 1, p1 

    Background: Pseudomonas aeruginosa is among the most common bacterial pathogens with wide spread distribution in health care settings. Despite advances in medical and surgical care and introduction of wide variety of antimicrobial agents, Pseudomonas aeruginosa continues to cause life...

  • Immunotherapy of Pseudomonas Infections.  // Annals of Internal Medicine;Feb67, Vol. 66 Issue 2, p443 

    Editorial. Comments on the significance of immunotherapy in pseudomonas aeruginosa infections. Increase of pseudonomas infections; Effectivity of antibiotics; Steps toward immunotherapy.

  • Patients with cystic fibrosis (CF) now have provincial formulary access to Novartis' TOBI PODHALER in Quebec.  // PharmacoEconomics & Outcomes News;10/15/2011, Issue 639, p9 

    The article reports that Novartis' PODHALER, a dry-powder formulation of tobramycin in the form of breath-activated inhaler, is available for patients with cystic fibrosis (CF) in Quebec for treatment of Pseudomonas aeruginosa (Pa) infections.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics